Direct Inhibition of δ-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute MI - DELTA MI – Presented at ACC 2007


The goal of the trial was to evaluate treatment with the novel δ-protein kinase C inhibitor KAI-9803 compared with placebo among patients with ST-elevation myocardial infarction (MI) undergoing primary percutaneous coronary intervention (PCI).